Effect of chronic endothelin receptor antagonism on cerebrovascular function in type 2 diabetes

Alex K. Harris, Mostafa M. Elgebaly, Weiguo Li, Kamakshi Sachidanandam, Adviye Ergul

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Diabetes increases the risk of stroke and contributes to poor clinical outcomes in this patient population. Myogenic tone of the cerebral vasculature, including basilar arteries, plays a key role in controlling cerebral blood flow. Increased myogenic tone is ameliorated with ET receptor antagonism in Type 1 diabetes. However, the role of endothelin-1 (ET-1) and its receptors in cerebrovascular dysfunction in Type 2 diabetes, a common comorbidity in stroke patients, remains poorly elucidated. Therefore, we hypothesized that 1) cerebrovascular dysfunction occurs in the Goto-Kakizaki (GK) model of Type 2 diabetes, and 2) pharmacological antagonism of ETA receptors ameliorates, while ETB receptor blockade augments vascular dysfunction. GK or control rats were treated with antagonists to either ET A (atrasentan, 5 mg·kg-1·day-1) or ETB (A-192621, 15 or 30 mg·kg-1·day -1) receptors for 4 wk and vascular function of basilar arteries was assessed using a wire myograph. GK rats exhibited increased sensitivity to ET-1. ETA receptor antagonism caused a rightward shift, indicating decreased sensitivity in diabetes, while it increased sensitivity to ET-1 in control rats. Endothelium-dependent relaxation was impaired in diabetes. ET A receptor blockade restored relaxation to control values in the GK animals with no significant effect in Wistar rats and ETB blockade with 30 mg·kg-1·day-1 A-192621 caused paradoxical constriction in diabetes. These studies demonstrate that cerebrovascular dysfunction occurs and may contribute to altered regulation of myogenic tone and cerebral blood flow in diabetes. While ETA receptors mediate vascular dysfunction, ETB receptors display differential effects. These results underscore the importance of ET A/ETB receptor balance and interactions in cerebrovascular dysfunction in diabetes.

Original languageEnglish (US)
JournalAmerican Journal of Physiology - Regulatory Integrative and Comparative Physiology
Volume294
Issue number4
DOIs
StatePublished - Apr 1 2008

Fingerprint

Endothelin Receptors
A 192621
Cerebrovascular Circulation
Type 2 Diabetes Mellitus
Blood Vessels
Basilar Artery
Endothelin-1
Stroke
Endothelin A Receptors
Type 1 Diabetes Mellitus
Constriction
Endothelium
Comorbidity
Wistar Rats
Pharmacology
Population

ASJC Scopus subject areas

  • Physiology
  • Physiology (medical)

Cite this

Effect of chronic endothelin receptor antagonism on cerebrovascular function in type 2 diabetes. / Harris, Alex K.; Elgebaly, Mostafa M.; Li, Weiguo; Sachidanandam, Kamakshi; Ergul, Adviye.

In: American Journal of Physiology - Regulatory Integrative and Comparative Physiology, Vol. 294, No. 4, 01.04.2008.

Research output: Contribution to journalArticle

Harris, Alex K. ; Elgebaly, Mostafa M. ; Li, Weiguo ; Sachidanandam, Kamakshi ; Ergul, Adviye. / Effect of chronic endothelin receptor antagonism on cerebrovascular function in type 2 diabetes. In: American Journal of Physiology - Regulatory Integrative and Comparative Physiology. 2008 ; Vol. 294, No. 4.
@article{3a901939423740e38cecdb2c2cb3c2b8,
title = "Effect of chronic endothelin receptor antagonism on cerebrovascular function in type 2 diabetes",
abstract = "Diabetes increases the risk of stroke and contributes to poor clinical outcomes in this patient population. Myogenic tone of the cerebral vasculature, including basilar arteries, plays a key role in controlling cerebral blood flow. Increased myogenic tone is ameliorated with ET receptor antagonism in Type 1 diabetes. However, the role of endothelin-1 (ET-1) and its receptors in cerebrovascular dysfunction in Type 2 diabetes, a common comorbidity in stroke patients, remains poorly elucidated. Therefore, we hypothesized that 1) cerebrovascular dysfunction occurs in the Goto-Kakizaki (GK) model of Type 2 diabetes, and 2) pharmacological antagonism of ETA receptors ameliorates, while ETB receptor blockade augments vascular dysfunction. GK or control rats were treated with antagonists to either ET A (atrasentan, 5 mg·kg-1·day-1) or ETB (A-192621, 15 or 30 mg·kg-1·day -1) receptors for 4 wk and vascular function of basilar arteries was assessed using a wire myograph. GK rats exhibited increased sensitivity to ET-1. ETA receptor antagonism caused a rightward shift, indicating decreased sensitivity in diabetes, while it increased sensitivity to ET-1 in control rats. Endothelium-dependent relaxation was impaired in diabetes. ET A receptor blockade restored relaxation to control values in the GK animals with no significant effect in Wistar rats and ETB blockade with 30 mg·kg-1·day-1 A-192621 caused paradoxical constriction in diabetes. These studies demonstrate that cerebrovascular dysfunction occurs and may contribute to altered regulation of myogenic tone and cerebral blood flow in diabetes. While ETA receptors mediate vascular dysfunction, ETB receptors display differential effects. These results underscore the importance of ET A/ETB receptor balance and interactions in cerebrovascular dysfunction in diabetes.",
author = "Harris, {Alex K.} and Elgebaly, {Mostafa M.} and Weiguo Li and Kamakshi Sachidanandam and Adviye Ergul",
year = "2008",
month = "4",
day = "1",
doi = "10.1152/ajpregu.00885.2007",
language = "English (US)",
volume = "294",
journal = "American Journal of Physiology - Heart and Circulatory Physiology",
issn = "0363-6135",
publisher = "American Physiological Society",
number = "4",

}

TY - JOUR

T1 - Effect of chronic endothelin receptor antagonism on cerebrovascular function in type 2 diabetes

AU - Harris, Alex K.

AU - Elgebaly, Mostafa M.

AU - Li, Weiguo

AU - Sachidanandam, Kamakshi

AU - Ergul, Adviye

PY - 2008/4/1

Y1 - 2008/4/1

N2 - Diabetes increases the risk of stroke and contributes to poor clinical outcomes in this patient population. Myogenic tone of the cerebral vasculature, including basilar arteries, plays a key role in controlling cerebral blood flow. Increased myogenic tone is ameliorated with ET receptor antagonism in Type 1 diabetes. However, the role of endothelin-1 (ET-1) and its receptors in cerebrovascular dysfunction in Type 2 diabetes, a common comorbidity in stroke patients, remains poorly elucidated. Therefore, we hypothesized that 1) cerebrovascular dysfunction occurs in the Goto-Kakizaki (GK) model of Type 2 diabetes, and 2) pharmacological antagonism of ETA receptors ameliorates, while ETB receptor blockade augments vascular dysfunction. GK or control rats were treated with antagonists to either ET A (atrasentan, 5 mg·kg-1·day-1) or ETB (A-192621, 15 or 30 mg·kg-1·day -1) receptors for 4 wk and vascular function of basilar arteries was assessed using a wire myograph. GK rats exhibited increased sensitivity to ET-1. ETA receptor antagonism caused a rightward shift, indicating decreased sensitivity in diabetes, while it increased sensitivity to ET-1 in control rats. Endothelium-dependent relaxation was impaired in diabetes. ET A receptor blockade restored relaxation to control values in the GK animals with no significant effect in Wistar rats and ETB blockade with 30 mg·kg-1·day-1 A-192621 caused paradoxical constriction in diabetes. These studies demonstrate that cerebrovascular dysfunction occurs and may contribute to altered regulation of myogenic tone and cerebral blood flow in diabetes. While ETA receptors mediate vascular dysfunction, ETB receptors display differential effects. These results underscore the importance of ET A/ETB receptor balance and interactions in cerebrovascular dysfunction in diabetes.

AB - Diabetes increases the risk of stroke and contributes to poor clinical outcomes in this patient population. Myogenic tone of the cerebral vasculature, including basilar arteries, plays a key role in controlling cerebral blood flow. Increased myogenic tone is ameliorated with ET receptor antagonism in Type 1 diabetes. However, the role of endothelin-1 (ET-1) and its receptors in cerebrovascular dysfunction in Type 2 diabetes, a common comorbidity in stroke patients, remains poorly elucidated. Therefore, we hypothesized that 1) cerebrovascular dysfunction occurs in the Goto-Kakizaki (GK) model of Type 2 diabetes, and 2) pharmacological antagonism of ETA receptors ameliorates, while ETB receptor blockade augments vascular dysfunction. GK or control rats were treated with antagonists to either ET A (atrasentan, 5 mg·kg-1·day-1) or ETB (A-192621, 15 or 30 mg·kg-1·day -1) receptors for 4 wk and vascular function of basilar arteries was assessed using a wire myograph. GK rats exhibited increased sensitivity to ET-1. ETA receptor antagonism caused a rightward shift, indicating decreased sensitivity in diabetes, while it increased sensitivity to ET-1 in control rats. Endothelium-dependent relaxation was impaired in diabetes. ET A receptor blockade restored relaxation to control values in the GK animals with no significant effect in Wistar rats and ETB blockade with 30 mg·kg-1·day-1 A-192621 caused paradoxical constriction in diabetes. These studies demonstrate that cerebrovascular dysfunction occurs and may contribute to altered regulation of myogenic tone and cerebral blood flow in diabetes. While ETA receptors mediate vascular dysfunction, ETB receptors display differential effects. These results underscore the importance of ET A/ETB receptor balance and interactions in cerebrovascular dysfunction in diabetes.

UR - http://www.scopus.com/inward/record.url?scp=41749092326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41749092326&partnerID=8YFLogxK

U2 - 10.1152/ajpregu.00885.2007

DO - 10.1152/ajpregu.00885.2007

M3 - Article

VL - 294

JO - American Journal of Physiology - Heart and Circulatory Physiology

JF - American Journal of Physiology - Heart and Circulatory Physiology

SN - 0363-6135

IS - 4

ER -